22nd Century Group to make further advances into cannabinoid production

US firm 22nd Century Group plans to use its expertise in plant science, biotechnology and genetics to move further into cannabinoid production.

Announcing its full-year results for 2021, the company said it generated its first revenue from hemp/cannabis IP and plant lines in the fourth quarter of 2021.

Part of this came from a three-way non-exclusive licence of the Anandia biosynthesis IP (jointly owned with Aurora Cannabis) to Cronos Group, to assist in the advancement of biosynthetic cannabinoids

Read full article
I'm already a subscriber

Freddie Dawson

Senior news editor
Freddie studied at King’s College, London and City University and worked for publications including The Times, The Malay Mail, PathfinderBuzz and Solar Summary before joining the CannIntelligence team. He has extensive experience in covering fast-moving consumer goods (FMCG), manufacturing and technological innovation.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization